Point72 Asset Management
DRUG

Point72 Asset Management’s Bright Minds Biosciences DRUG Stock Holding History

Point72 Asset Management’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-105,020
Closed -$6.37M – 3964
2025
Q3 		$6.37M Sell
105,020
-30,000
-22% -$1.16M 0.01% 977
2025
Q2 		$3.53M Hold
135,020
– – 0.01% 1089
2025
Q1 		$4.87M Sell
135,020
-169
-0.1% -$6.19K 0.01% 936
2024
Q4 		$4.87M Buy
+135,189
New +$4.76M 0.01% 953

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Point72 Asset Management's DRUG Position: Q4 2025 in Review

Point72 Asset Management sold out of Bright Minds Biosciences (DRUG) in Q4 2025, closing a stake of 105,020 shares — an estimated $6.37M sold.

Point72 Asset Management first reported a position in DRUG in Q4 2024 and held it in 4 quarters. The position peaked at $6.37M in Q3 2025. 74 funds tracked by Wall St. Rank hold DRUG as of Q4 2025.

  • Point72 Asset Management reported no remaining Bright Minds Biosciences position as of Q4 2025 after selling out during the quarter.
  • Point72 Asset Management sold 105,020 Bright Minds Biosciences shares in Q4 2025, an estimated $6.37M.
  • Point72 Asset Management first reported a position in Bright Minds Biosciences in Q4 2024 and held it in 4 quarters.
  • Point72 Asset Management's Bright Minds Biosciences position peaked at $6.37M in Q3 2025.
  • 74 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q4 2025.

Based on Point72 Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.